CVKD Cadrenal Therapeutics, Inc. Common Stock
USHealthcareAs of 2026-07-10 16:00
Why CVKD matters now
Cadrenal Therapeutics, Inc. Common Stock (CVKD) is a US stock in Healthcare. The latest InvestLog snapshot shows $2.89 with -3.99% on the session and $8.9M in market capitalization; recent performance reads 1-month -29.58% and YTD -48.38%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-2.5M, and EPS of $-1.04. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -109.1%.
The latest indexable market news headline is "Cadrenal Therapeutics Announces up to $8.8 Million Private Placement Priced At-The-Market Under Nasdaq Rules" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $32.00; recent insider activity includes Pham Quang X filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
4.69
P/S
0.00
EV/EBITDA
-0.65
DCF Value
$1.72
FCF Yield
-109.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-411.0%
ROA
-415.4%
ROIC
-670.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-2.5M | $-1.04 |
| Q4 2025 | $0.00 | $-3.0M | $-1.41 |
| FY 2025 | $0.00 | $-13.2M | $-6.64 |
| Q3 2025 | $0.00 | $-2.7M | $-1.31 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$32.00
Target (Median)
$32.00
Target Range
$32.00 - $32.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.61
Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development. The company's core focus is the advancement of Tecarfarin, a novel therapeutic agent that has received orphan drug designation. This treatment is engineered to prevent systemic thromboembolism originating from cardiac issues in patients suffering from both end-stage renal disease and atrial fibrillation. Established in 2022, the firm is headquartered in Ponte Vedra, Florida.